Nitric oxide in cardiac transplantation

Vascular Disease Prevention

Volumn 2, Issue 1, 2005, Pages 77-85

  Podesser, Bruno K ^a,c   Gottardi, Roman ^a   Seitelberger, Rainald ^a   Hallström, Seth ^a,b  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b MEDICAL UNIVERSITY OF GRAZ   (Austria)

^c LUDWIG BOLTZMANN INSTITUTE FOR LUNG VASCULAR RESEARCH   (Austria)

Author keywords

Donor and recipient management; Heart transplantation; Nitric oxide

Indexed keywords

1 HYDROXY 2 OXO 3 (N 3 METHYLAMINOPROPYL) 3 METHYL 1 TRIAZENE; ACETYLSALICYLIC ACID; AMD 6221; AMINOGUANIDINE; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ARGININE; CYCLOHEXIMIDE; DACTINOMYCIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLYCERYL TRINITRATE; IMMUNOSUPPRESSIVE AGENT; N ACETYL S NITROSOPENICILLAMINE; N(G) METHYLARGININE; N(G) NITROARGININE METHYL ESTER; NCX 4040; NITRIC OXIDE; NITRIC OXIDE DONOR; NITROPRUSSIDE SODIUM; NOC 7; PEPTIDE DERIVATIVE; S NITROSOCYSTEINE; S NITROSOGLUTATHIONE; SCAVENGER; TETRAHYDROBIOPTERIN; UNCLASSIFIED DRUG;

CORONARY ARTERY; CORONARY ARTERY BLOOD FLOW; ENDOTHELIUM CELL; HEART FAILURE; HEART FUNCTION; HEART MUSCLE CELL; HEART MUSCLE ISCHEMIA; HEART MUSCLE REPERFUSION; HEART PRESERVATION; HEART PROTECTION; HEART TRANSPLANTATION; HUMAN; HUMAN CELL; INDUCED HYPOTHERMIA; MOUSE; NONHUMAN; ORGAN DONOR; PARACRINE SIGNALING; PERIOPERATIVE PERIOD; PRIORITY JOURNAL; RAT; RECIPIENT; REGULATORY MECHANISM; REVIEW; SURVIVAL RATE; VASCULAR ENDOTHELIUM;

EID: 20044378369     PISSN: 15672700     EISSN: None     Source Type: Journal    
DOI: 10.2174/1567270052774377     Document Type: Review

References (115)

1. http://concise.britannica.com/ebc/article?eu=398846. Accessed May 6, 2004
2. Arnold WP, Mittal CK, Katsuki S, Murad F. Nitric oxide activates guanylate cyclase and increases guanosine 3′:5′-cyclic monophosphate levels in various tissue preparations. Proc Natl Acad Sci USA 1977; 74: 3203-7.
3. Katsuki S, Arnold W, Mittal C, Murad F. Stimulation of guanylate cyclase by sodium nitroprusside, nitroglycerin and nitric oxide in various tissue preparations and comparison to the effects of sodium azide and hydroxylamine. J Cyclic Nucleotide Res 1977; 3: 23-35.
4. Furchgott RF, Zawadzki JV. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature 1980; 288: 373-6.
5. Ignarro LJ, Buga GM, Wood KS. et al. Endothelium-derived relaxing factor produced and released from artery and vein is nitric oxide. Proc Natl Acad Sci USA 1987; 84: 9265-9269.
6. Palmer RM, Ferrige AG, Moncada S. Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature 1987; 327: 524-6.
7. Koshland DE Jr. The molecule of the year. Science 1992; 58: 1861.
8. Pinsky DJ, Patton S, Mesaros S, et al. Mechanical transduction of nitric oxide synthesis in the beating heart. Circ Res 1997; 81: 372-9.
9. Linz W, Wiemer G, Schoelkens BA. ACE-inhibition induces NO-formation in cultured bovine endothelial cells and protects ischemic rat hearts. J Mol Cell Cardiol 1992; 24: 909-919.
10. Balligand JL, Cannon PJ. Nitric oxide synthases and cardiac muscle. Arterioscler Thromb Vasc Biol 1997; 17: 1846-58
11. Wu KK. Regulation of endothelial nitric oxide synthase activity and gene expression. Ann N Y Acad Sci 2002; 962: 122-30
12. Kojda G, Kottenberg K. Regulation of basal myocardial function by NO. Cardiovasc Res 1999; 41: 514-23.
13. Michael T. Gewaltig, Georg Kojda. Vasoprotection by nitric oxide: mechanisms and therapeutic potential. Cardiovascular Research 2002; 55: 250-260.
14. Moncada S, Palmer RM, Higgs EA. Nitric oxide: phsiology, pathophsiology and pharmacology. Pharmacol Rev 1991; 43: 109-42.
15. Ignarro LJ, Buga GM, Wood KS, et al. Endothelium-derived relaxing factor produced and released from artery and vein is nitric oxide. Proc Natl Acad Sci USA 1987; 84: 9265-9.
16. Azuma H, Ishikawa M, Sekizaki. Endothelium-dependent inhibition of platelet aggregation. Br J Pharmacol 1986; 88: 411-415.
17. Kalinowski L, Matys T, Chabielska E, et al. Angiotensin II ATI receptor antagonists inhibit platelet adhesion and aggregation by nitric oxide release. Hypertension 2002; 40: 521-7.
18. Radomski MW, Palmer RMJ, Moncada S. Endogenous nitric oxide inhibits human platelet adhesion to vascular endothelium. Lancet 1987; 1057-1058.
19. Recchia FA, McConnell PI, Loke KE, et al. Nitric oxide controls cardiac substrate utilization in the conscious dog. Cardiovasc Res 1999; 44: 325-32.
20. Loke KE, McConnell PI, Tuzman JM, et al. Endogenous endothelial nitric oxide synthase-derived nitric oxide is a physiological regulator of myocardial oxygen consumption. Circ Res 1999; 84: 840-5.
21. Paulus WJ, Shah AM. NO and cardiac diastolic function. Cardiovasc Res 1999; 43: 595-606.
22. Kanai AJ, Mesaros S, Finkel MS, et al. Beta-adrenergic regulation of constitutive nitric oxide synthase in cardiac myocytes. Am J Physiol 1997; 273: C1371-7.
23. Brady AJ, Warren JB, Poole-Wilson PA et al. Nitric oxide attenuates cardiac myocyte contraction. Am J Physiol 199; 265: H176-82.
24. Mungrue IN, Bredt DS, Stewart DJ et al. From molecules to mammals: what's NOS got to do with it? Acta Physiol Scand 2003; 179: 123-35.
25. Walford G, Loscalzo J. Nitric oxide in vascular biology. J Thromb Haemost 2003; 1: 2112-8
26. Landmesser U, Hornig B, Drexler H. Endothelial function: a critical determinant in atherosclerosis? Circulation 2004; 109: 1127-33.
27. Secco DD, Paron JA, de Oliveira SH, Fereirra SH, Silva JS, Cunha Fde Q. Neutrophil migration in inflammation: nitric oxide inhibits rolling, adhesion and in duces apoptosis. Nitric Oxide 2003; 9: 153-64.
28. Ashley EA, Sears CE, Bryant SM, Watkins HC, Casadei B. Cardiac nitric oxide synthase I regulates basal and beta-adrenergic contractility in murine ventricular myocytes. Circulation 2002; 105: 3011-6.
29. Feron O, Dessy C, Moniotte S, Desager JP, Balligand JL. Hypercholerolemia decreases nitric oxide production by promoting the interaction of caveolin and endothelial nitric oxide synthase. J Clin Invest 1999; 103: 897-905.
30. Sharma R, Davidoff MN. Oxidative stress and endothelial dysfunction in heart failure. Congest Heart Fail 2002; 8: 165-72.
31. Nakamura K, Schmidt I, Gray CC et al. The effect of chronic L-arginine administration on vascular recovery following cold cardioplegic arrest in rats. Eur J Cardiothorac Surg 2002; 21: 753-9.
32. Li H, Wallerath T, Munzel T, Forstermann U. Regulation of endothelial-type NO synthase expression in pathophysiology and in response to drugs. Nitric Oxide 2002; 7: 149-64.
33. Korthuis RJ, Granger DN, Townsley MI et al. The role of oxygen - derived free radicals in ischemia induced increases in canine skeletal muscle vascular permeability. Circ Res 1985; 57: 599-609.
34. Sternbergh WC, Makhoul RG, Adelman B. Nitric oxide mediated endothelium dependent vasodilation is selectively attenuated in the postischemic extremity. Surgery 1993; 114: 960-967.
35. Baue AE. The horror autotoxicus and multiple-organ failure. Arch Surg 1992; 127: 1451-1462.
36. Grace PA. Ischemia-reperfusion injury. Brit J Surg 1994; 81: 637-647.
37. Huk I, Nanobashvili J, Neumayer C et al. L-arginine treatment alters the kinetics of nitric oxide and superoxide release and reduces ischemia/reperfusion injury in skeletal muscle. Circulation 1997; 96: 667-75.
38. Valantine HA. Cardiac allograft vasculopathy: central role of endothelial injury leading to transplant "atheroma". Transplantation 2003; 76: 891-9.
39. Weis M, Cooke JP. Cardiac allograft vasculopathy and dysregulation of the NO synthase pathway. Arterioscler Thromb Vasc Biol 2003; 23: 567-75.
40. Laude K, Thuillez C, Richard V. Coronary endothelial dysfunction after ischemia and reperfusion: a new therapeutic target? Braz J Med Biol Res 2001; 34: 1-7.
41. Gourine AV, Gonon AT, Pernow J. Involvement of nitric oxide in cardioprotective effect of endothelin receptor antagonist during ischemia-reperfusion. Am J Physiol Heart Circ Physiol 2001; 280: H1105-12.
42. Bolli R. Mechanism of myocardial "stunning". Circulation 1990; 82: 723-38.
43. Jahania MS, Sanchez JA, Narayan P, Lasley RD, Mentzer RM Jr. Heart preservation for transplantation: principles and strategies. Ann Thorac Surg 1999; 68: 1983-7.
44. Redondo J, Manso AM, Pacheco ME, Hernandez L, Salaices M, Marin J. Hypothermic storage of coronary endothelial cells reduces nitric oxide synthase activity and expression. Cryobiology 2000; 41: 292-300.
45. Wheeldon D, Sharpies L, Wallwork J English T. Donor heart preservation survey. J Heart Lung transplant 1992; 11: 986-993.
46. Southard JH, Belzer FO. Organ preservation. Ann Rev med 1995; 46: 235-247.
47. Parolari A, Rubini P, Cannata A, et al. Endothelial damage during myocardial preservation and storage. Ann Thorac Surg 2002; 73: 682-90.
48. Ardehali A, Hughes K, Sadeghi A, Esmailian F, Marelli D, Moriguchi J. Inhaled nitric oxide for pulmonary hypertension after heart transplantation. Transplantation 2001; 72: 638-41.
49. Stobierska-Dzierzek B, Awad H, Michler RE. The evolving management of acute right-sided heart failure in cardiac transplant recipients. J Am Coll Cardiol 2001; 38: 923-31.
50. Kieler-Jensen N, Lundin S, Ricksten SE. Vasodilator therapy after heart transplantation: effects of inhaled nitric oxide and intravenous prostacyclin, prostaglandin E1, and sodium nitroprusside. J Heart Lung Transplant 1990; 9: 644-651.
51. Ardehali A, Hughes K, Sadeghi A, et al. Inhaled nitric oxide for pulmonary hypertension after heart transplantation. Transplantation 2001; 72: 638-41.
52. Fullerton DA, McIntyre RC Jr. Inhaled Nitric oxide: Therapeutic Applications in Cardiothoracic Surgery. Ann Thorac Surg 1996; 61: 1856-64
53. Wang T, El Kebir D, Blaise G. Inhaled nitric oxide in 2003: a review of its mechanisms of action. Can J Anaesth 2003; 50: 839-46.
54. Pflugfelder PW, Huff M, Oskalns R, Rudas L, Kostuk WJ. Cholesterol-lowering therapy after heart transplantation; a 12-month randomized trial. J Heart Lung Transplantation 1995; 14: 613-22.
55. Weis M, Wildhirt SM, Schulze C, et al. Coronary vasomotor dysfunction in the cardiac allograft: impact of different immunosuppressive regimens. J cardiovasc Pharmacol 2000; 36: 776-84.
56. Lou H, Kodama T, Wang YN, Katz N, Ramwell P, Foegh ML. L-arginine prevents heart transplant arteriosclerosis by modulating the vascular cell proliferative response to insulin-like growth factor-1 and interleukin-6. J Heart Lung Transplant 1996; 15: 1248-57.
57. Iwata A, Sai S, Nitta Y, et al. Liposome-mediated gene transfection of endothelial nitric oxide synthase reduces endothelial activation and leukocyte infiltration in transplanted hearts. Circulation 2001; 103: 2753-9.
58. Shukla N, Angelini GD, Ascione R, Talpahewa S, Capoun R, Jeremy J. Nitric oxide donating aspirins: novel drugs for the treatment of saphenous vein graft failure. Ann Thorac Surg 2003; 75: 1437-42.
59. Pieper GM, Cooper M, Johnson CP, Adams MB, Felix CC, Roza AM. Reduction of myocardial nitrosyl complex formation by a nitric oxide scavenger prolongs cardiac allograft survival. J Cardiovasc Pharmacol 2000; 35: 114-20.
60. Albrecht EW, Stegeman CA, Tiebosch AT, Tegzess AM, van Goor H. Expression of inducible and endothelial nitric oxide syntheses, formation of peroxynitrite and reactive oxygen species in human chronic renal transplant failure. Am J Transplant 2002; 2: 448-53.
61. Cannon P, Yang X, Szabolcs MJ, Ravalli S, Sciacca RR, Michler RE. The role of inducible nitric oxide synthase in cardiac allograft rejection. Cardiovasc Res 1998; 38: 6-15.
62. Cue MO, Furman BL, Paratt JR. Modification of alpha-adrenoceptor-mediated pressor responses by NG-nitro-L-arginine methyl ester and vasopressin in endotoxin-treated pithed rats. Eur J Pharmacol 1992; 224: 63-9.
63. Knowles RG, Salter M, Brooks SL, Moncada S. Anti-inflammatory glucocorticoids inhibit the induction by endotoxin of nitric oxide synthase in the lung, liver and aorta of the rat. Biochem Biophys Res Commun 1990; 172: 1042-8.
64. Radomski MW, Palmer RM, Moncada S. Glucocorticoids inhibit the expression of an inducible, but not the constitutive, nitric oxide synthase in vascular endothelial cells. Proc Natl Acad Sci USA 1990; 87: 10043-7.
65. Rees DD, Cellek S, Palmer RM, Moncada S. Dexamethasone prevents the induction by endotoxin of a nitric oxide synthase and the associated effects on vascular tone: an insight into endotoxin shock. Biochem Biophys Res Commun 1990; 173: 541-7.
66. Smith RE, Palmer RM, Moncada S. Coronary vasodilatation induced by endotoxin in the rabbit isolated perfused heart is nitric oxide-dependent and inhibited by dexamethasone. Br J Pharmacol 1991; 104: 5-6.
67. Gardiner SM, Kemp PA, Benett T, Palmer RMJ, Monada S. Regional and cardiac haemodynamic effects of NG-NG, dimethyl-L - arginine and their reversibility by vasodilators in conscious rats. Br J Pharmacol 1993; 110: 1457-1464.
68. Petros A, Lamb G, Leone A, Moncada S, Benett D, Vallance P. Effect of nitric oxide synthase inhibitors on hypertension in patients with septic shock. Cardiovasc Res 1994; 28: 34-39
69. Radomski MW, Vallance P, Whitley G, Foxwell N, Moncada S. Platelet adhesion to human vascular endothelium is modulated by constitutive and cytokine induced nitric oxide. Cardiovasc Res 1993; 27: 1380-2.
70. Chaturvedi RR, Hjortdal VE, Stenbog EV, et al. Inhibition of nitric oxide synthesis improves left ventricular contractility in neonatal pigs late after cardiopulmonary bypass. Heart 1999; 82: 740-4.
71. Kielstein JT, Impraim B, Simmel S, et al. Cardiovascular effects of systemic nitric oxide synthase inhibition with asymmetrical dimethylarginine in humans. Circulation 2004; 109: 172-7.
72. Russell ME, Wallace AF, Wyner LR, Newell JB, Kamovsky MJ. Upregulation and modulation of inducible nitric oxide synthase in rat cardiac allografts with chronic rejection and transplant arteriosclerosis. Circulation 1995; 92: 457-64.
73. Roza AM, Cooper M, Pieper G, et al. NOX 100, a nitric oxide scavenger, enhances cardiac allograft survival and promotes long-term graft acceptance. Transplantation 2000; 69: 227-31.
74. Pieper GM, Roza AM, Adams MB, et al. A ruthenium (III) polyaminocarboxylate complex, a novel nitric oxide scavenger, enhances graft survival and decreases nitrosylated heme protein in models of acute and delayed cardiac transplant rejection. J Cardiovasc Pharmacol 2002; 39: 441-8.
75. Matthias J. Szabolcs, Ji Sun, Ningsheng M, et al. Effects of Selective Inhibitors of Nitric Oxide Synthase-2 Dimerization on Acute Cardiac Allograft Rejection. Circulation 2002; 106: 2392-2396.
76. Soto PF, Jia CX, Rabkin DG, et al. Improvement of rejection-induced diastolic abnormalities in rat cardiac allografts with inducible nitric oxide synthase inhibition. J Thorac Cardiovasc Surg 2000; 120: 39-46.
77. Perrault LP, Malo O, Bidouard JP, et al. Inhibiting the NO pathway with intracoronary L-NAME infusion increases endothelial dysfunction and intimal hyperplasia after heart transplantation. J Heart Lung Transplant 2003; 22: 439-51.
78. Johnson G 3rd, Tsao PS, Lefer AM. Cardioprotective effects of authentic nitric oxide in myocardial ischemia with reperfusion. Crit Care Med 1991; 19: 244-252.
79. Siegfried MR, Carey C, Ma XL, Lefer AM. Beneficial effects of SPM-5185, a cysteine-containing NO donor in myocardial ischemia-reperfusion. Am J Physiol 1992; 263: H771-H777.
80. Bilinska M, Maczewski M, Beresewicz A. Donors of nitric oxide mimic effects of ischemic preconditioning on perfusion induced arrhythmias in isolated rat hearts. Mol Cell Biochem 1996; 161: 265-271.
81. Shiraishi Y, Lee JR, Laks H, et al. L-Arginine administratiuon during reperfusion improves pulmonary function. Ann Thorac Surg 1996; 62: 1580-1587.
82. Pinsky DJ, Oz MC, Koga S, et al. Cardiac preservation is enhanced in a heterotopic rat transplant model by supplementing the nitric oxide pathway. J Clin Invest 1994; 93: 2291-2297.
83. Yamashita M, Schmid RA, Ando K, Cooper JD, Patterson GA. Nitroprusside ameliorates lung allograft injury. Ann Thorac surg 1996; 62: 791-796.
84. Du ZY, Hicks M, Jansz P, Rainer S, Spratt P, Macdonald P. The nitric oxide donor, diethylamine NONOatc, enhances preservation of the donor rat heart. J Heart Lung Transplant 1998; 17: 1113-1120.
85. Skarsgard PL, McManus BM, van Breemen C, Laher I. Endothelium-smooth muscle interaction in cardiac transplantation. Clin Exp Pharmacol and Physiol 1998; 25; 836-840.
86. Huk I, Nanobashvili J, Neumayer C et al. L-arginine treatment alters the kinetics of nitric oxide and superoxide release and reduces ischemia/reperfusion injury in skeletal muscle. Circulation 1997; 96: 667-675.
87. Caus T, Desrois M, Izquierdo M et al. NOS substrate during cardioplegic arrest and cold storage decreases stunning after heart transplantation in a rat model. J Heart Lung Transplant 2003; 22: 184-91.
88. Carrier M, Pellerin M, Perrault LP, et al. Cardioplegic arrest with L-arginine improves myocardial protection: results of a prospective randomized clinical trial. Ann Thorac Surg 2002; 73: 837-41.
89. Mesaros S, Grunfeld S, Mesarosova A, Malinski T. New strategy for prolonging the preservation time of hearts for transplantation. Physiol Res 1997; 46: 251-5.
90. Andrasi TB, Soos P, Bakos G, et al. L-arginine protects the mesenteric vascular circulation against cardiopulmonary bypass-induced vascular dysfunction. Surgery 2003; 134: 72-9.
91. Labarrere CA, Deng MC. Microvascular prothrombogenicity and transplant coronary artery disease. Transpl Immunol 2002; 9: 243-9.
92. Stoica SC, Goddard M, Large SR. The endothelium in clinical cardiac transplantation. Ann Thorac Surg 2002; 73: 1002-8.
93. Pinsky DJ. The vascular biology of the heart and lung preservation for transplantation. Thrombosis Hemostasis 1995; 74: 58-65.
94. Tsao PS. Time course of endothelial dysfunction and myocardial ischemia and reperfusion in the cat. Circulation 1990; 82: 1402-1412.
95. Hallstrom S, Gasser H, Neumayer C, et al. S-nitroso human serum albumin treatment reduces ischemia/reperfusion injury in skeletal muscle via nitric oxide release. Circulation 2002; 105: 3032-8.
96. Semsroth S, Franz M, Fellner B et al. Nitric oxide substitution during ischemia/reperfusion improves hemodynamic and metabolic outcome of explanted rabbit hearts after long term ischemia. J Heart Lung Transplantation 2002; 21: 136 (abstract).
97. R. Gottardi, T. Szerafin, S. Semsroth, et al. S-nitroso-human serum albumin improves organ preservation in orthotopic heart transplantation in the pig. J Heart Lung Transplantation 2004; 23: 172 (abstract).
98. Takano H, Tang XL, Qiu Y, Guo Y, French BA, Bolli R. Nitric oxide donors induce late preconditioning against myocardial stunning and infarction in conscious rabbits via an antioxidant-sensitive mechanism. Circ Res 1998; 83: 73-84.
99. Konorev EA, Joseph J, Tarpey MM, Kalyanaraman B. The mechanism of cardioprotection by S-nitrosoglutathione monoethyl ester in rat isolated heart during cardioplegic ischaemic arrest. Br J Pharmacol 1996; 119: 511-8.
100. Langford EJ, Brown AS, Wainwright RJ, et al. Inhibition of platelet activity by S-nitrosoglutathione during coronary angioplasty. Lancet 1994; 344: 1458-60.
101. Mayers I, Salas E, Hurst T, Johnson D, Radomski MW. Increased nitric oxide synthase activity after canine cardiopulmonary bypass is suppressed by s-nitrosoglutathione. J Thorac Cardiovasc Surg 1999; 117: 1009-16.
102. Feelisch M, Schonafinger K, Noack E. Thiol-mediated generation of nitric oxide accounts for the vasodilator action of furoxans. Biochem Pharmacol 1992; 44: 1149-57.
103. Bolli R. Cardioprotective function of inducible nitric oxide synthase and role of nitric oxide in myocardial ischemia and preconditioning: an overview of a decade of research. J Mol Cell Cardiol 2001; 33: 1897-918.
104. Mungrue IN, Gros R, You X, Pirani A, Azad A, Csont T. Cardiomyocyte overexpression of iNOS in mice results in peroxynitrite generation, heart block, and sudden death. J Clin Invest 2002; 109: 735-43.
105. Caus T, Desrois M, Izquierdo M, et al. NOS substrate during cardioplegic arrest and cold storage decreases stunning after heart transplantation in a rat model. J Heart Lung Transplant 2003; 22: 184-91
106. Kai Y. Xu, Shanmuga P. Kuppusamy, Jing Q. Wang, et al. Nitric Oxide Protects Cardiac Sarcolemmal Membrane Enzyme Function and Ion Active Transport against Ischemia-induced Inactivation. J Biol Chem 2003; 278: 41798-41803.
107. Hartman JC. The role of bradykinin and nitric oxide in the cardioprotective action of ACE inhibitors. Ann Thorac Surg 1995; 60: 789-792.
108. Kitakaze M, Minamino T, Node K, et al. Beneficial effects of inhibition of angiotensin-concerting enzyme on ischemic myocardium during coronary hypoperfusion in dogs. Circulation 1995; 92: 950-961.
109. Zahler S, Kupatt Ch, Becker BF. ACE inhibition attenuates cardiac cell damage and preserves release of NO in the postischemic heart. Immunopharmacology 1999; 44: 27-33.
110. Korn P, Kröner A, Schirnhofer J et al. Quinaprilar during cardioplegic arrest prevents ischemia-reperfusion injury. J Thorac Cardiovasc Surg 2002; 124: 352-360.
111. The GISSI-3 APPI study Group. Early and six month outcome in patients with angina pectoris early after acute myocardial infarction (the GISSI-3 APPI study). Am J cardiol 1996; 78: 1191-1197.
112. Lazar H, Volpe C, Bao Y et al. Beneficial effects of angiotensin- converting enzyme inhibitors during acute revascularization. Ann Thorac Surg 1998; 66: 487-492.
113. Podesser, BK, Schirnhofer J, Bernecker OY, et al. Optimizing I/R injury in the failing rat heart-improved myocardial protection with acute ACE inhibition. Circulation 2002; 106: I-277-I-283.
114. Furukawa Y, Matsumori A, Hirozane T, Sasayama S. Angiotensin 11 receptor antagonist TCV-116 reduces graft coronary artery disease and preserves graft status in a murine model. A comparative study with captopril. Circulation 1996; 93: 333-339.
115. Perrault LP, Nicker C, Desjardins N, Dumont E, Thai P, Carrier M. Improved preservation of coronary endothelial function with Celsior compared with blood and crystalloid solutions in heart transplantation. J Heart Lung Transplant 2001; 20: 549-558.